Advertisement

Topics

Iconic Therapeutics, Inc. Company Profile

09:46 EDT 20th June 2018 | BioPortfolio

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. Iconic has completed a Phase 1 clinical trial in wet AMD and has initiated a Phase 2 study in newly diagnosed AMD patients. The company is investigating the ICON family of proteins in cancer and has initiated a research program in solid tumors. Iconic is backed by leading venture capital firms MPM Capital, H.I.G. Bioventures and Lundbeckfond Ventures. Please visit www.iconictherapeutics.com for additional information.


News Articles [856 Associated News Articles listed on BioPortfolio]

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pr...

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) --  Jounce Therape...

Results from the phase I ICONIC trial

Dr Yap speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about data from the ICONIC trial of ICOS agonist antibody JTX-2011, a first-in-class drug. He outlin...

Martin Guitar Unveils New Museum Exhibit Celebrating The Evolution Of The Iconic D-28

The multipanel exhibit tracks the development and evolution of the most iconic acoustic guitar in music history, from the cutting edge of guitar craftsmanship to Read more...

Marine charities net more than iconic fishery: Massachusetts

(University of Vermont) Massachusetts boasts one of the most iconic fisheries in the US, but new research suggests that protecting marine coastlines has surpassed commercial fishing as an economic dri...

CARA Abuzz, CERS Up 20% In 5 Days, KURA Turns Heads, JNCE Making Iconic Moves

Cara Therapeutics Inc. gained 17.20% to close Wednesday's trading at $16.08. The Company's lead drug candidate is I.V. CR845, which is under a phase III safety study for the treatment of chronic kidne...

Newstrike Resources Ltd. (TSX VENTURE: $HIP.V) - The Tragically Hip Supports CMED & HIP Combination

TORONTO, ONTARIO - January 12, 2018 (Investorideas.com Newswire) Newstrike Resources Ltd. (TSX VENTURE:HIP) ("Newstrike") welcomes a statement from Canada's iconic musicians, The Tragically Hip, in st...

Reviving the American chestnut: Genetic modification can save the iconic tree from extinction

PubMed Articles [453 Associated PubMed Articles listed on BioPortfolio]

Do Children Understand Iconic Gestures About Events as Early as Iconic Gestures About Entities?

Children can understand iconic co-speech gestures that characterize entities by age 3 (Stanfield et al. in J Child Lang 40(2):1-10, 2014; e.g., "I'm drinking" [Formula: see text] tilting hand in C-sha...

A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD.

This phase 1 study evaluated the safety and tolerability of single intravitreous injections (IVIs) of ICON-1 (Iconic Therapeutics, South San Francisco, CA) in patients with neovascular age-related mac...

An Iconic Pit Viper of the Central American Rainforests.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project.

The ICONIC project has developed an automated high-throughput pipeline to generate HIV nearly full-length genomes (NFLG, i.e. from gag to nef) from next-generation sequencing (NGS) data. The pipeline ...

Clinical Trials [147 Associated Clinical Trials listed on BioPortfolio]

Cognitive Skills and Iconic Gestures

In this study, cognitive skills will be identified that underlie the production of iconic gestures in individuals with language difficulties. Specifically, what is the role of nonverbal se...

Effectiveness of the Iconic Therapy for Borderline Personality Disorder Symptoms

Borderline personality disorder (BPD) is the most prevalent personality disorder in young community population whose most severe complication is suicide. Pharmacotherapy should not be used...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1267 Associated Companies listed on BioPortfolio]

Iconic Therapeutics, Inc.

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal di...

Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal di...

ICONIC Protein

ICONIC Protein is one of the fastest-growing brands in the ready-to-drink protein beverage market with a passionate following of health-conscious consumers who have flocked to the...

Iconic Brands Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Iconic Therapeutics, Inc." on BioPortfolio

We have published hundreds of Iconic Therapeutics, Inc. news stories on BioPortfolio along with dozens of Iconic Therapeutics, Inc. Clinical Trials and PubMed Articles about Iconic Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Iconic Therapeutics, Inc. Companies in our database. You can also find out about relevant Iconic Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record